Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News & Press: News

ITOG Quarterly Newsletter June 2020

Wednesday, May 20, 2020   (1 Comments)
Posted by: Judy Dallas
Share |

ITOG Quarterly Newsletter June 2020 j

June 2020 ITOG

Quarterly Update E-Newsletter

Executive Committee

Manisha H. Shah, MD, Chair
The Ohio State University
Sareh Parangi, MD, Secretary
Harvard Medical School
Eric Sherman, MD Chair, Protocol Committee
Memorial Sloan-Kettering Cancer Center
Dwight Vicks Ill MBA, Treasurer
President, Vicks, Inc.

Board of Directors

Keith C. Bible, M.D., Ph.D.
Mayo Clinic (Rochester)
Naifa Busaidy, MD
MD Anderson Cancer Center
Maria Cabanillas, MD
MD Anderson Cancer Center
James Fagin, MD
Memorial Sloan-Kettering
Andrew Gianoukakis, MD
University of California, Los Angeles
Elizabeth Grubbs, MD
MD Anderson Cancer Center


Bryan Haugen, MD
University of Colorado, Health Sciences Center
Alan Ho MD, PhD
Memorial Sloan-Kettering
Sophie Leboulleux
Gustave Roussy
Gregory Randolph,
MD Massachusetts Eye and Ear Infirmary
Bruce G. Robinson, MD
University of Sydney
Julie Ann Sosa, M.D.
University of California, San Francisco

Message from the Chair

Manisha Shah, MD


Dear Friends,
I sincerely hope that you and your families are safe during COVID-19 pandemic. This pandemic has fundamentally changed how we interact with patients and each other, but it has not stopped our commitment and hard work at the ITOG. Our Board of Directors, Committees and Task Forces at ITOG continue to meet using video conferencing services.

I am thrilled to share your excitement about achieving agreat mile-stone in Management of RET-mutated Medullary Thyroid Cancer and RET-fusion Thyroid Canceras Selpercatinib (LOXO-292) was approved by Food and Drug Administration (FDA) on May 8 2020 for these indications.Please join me in congratulating incredible work, dedication and diligence of numerous members of ITOG for a pivotal international clinical trial leading to such a historic moment. I am excited to present (virtually) updates of this trial at theAmerican Society of Clinical Oncology(ASCO)Annual meetinglater this month.

Furthermore, both ongoing investigator-initiated clinical trials led by Drs. Alan Ho and Bryan Haugen at ITOG met the target accrual goals and results of one of such trials are being presented by Dr. Bryan Haugen at upcomingASCO Annual meeting.Protocol committee and Task Forces are working hard to build on this momentum to develop new trials to aid in catalyzing a cure for Thyroid Cancer.I urge you to continue your dedication and contribution to ongoing ITOG trials.

Finally, I am excited to announce that we are opening the Nominations and Elections Process today forfive (5) Board of Director-At-Large open Positions. Current members in good standing, including past Board of Directors are eligible to apply. Interested candidates may be nominated or self-nominated. This is a great opportunity to contribute to ITOG’s direction and future. We are extending the nomination and voting time frame to ensure that all members have ample time to participate.

If you would like to submit a nomination please see information below!



FDA Approval for Retevmo (selpercatinib)

Based on the clinical trial results from the LIBRETTO-001 (NCT03157128) Phase 1/2 trial inRET-altered thyroid cancer, RetevmoTM(selpercatinib) is now approved to treat advancedmedullary thyroid cancer (MTC) ...


Lori Wirth, MD

Massachusetts General Hospital

ACCRU-ITOG-1504Achieves Accrual Goal

CongratulationstoPrincipal Investigator: Bryan Haugen at TheUniversity of Colorado Cancer Centerand his team for achievingaccrual goal of 60ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive,Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study.


ITOG Active Clinical Trials

ACCRU/ITOG 1504 Combination lmmunothera1w with Multikinase Inhibitor (MKI) in Progressive, Radiodine­resistant Differentiated Thyroid Cancers
Accrual Status:Closed to Accrual
Accrual Goal: 60
Current Accrual: 60

PI:Bryan Haugen, MDUniversity of Colorado Cancer Center

Selumetinib Rius RAI for RAI-Avid Thyroid Cancers
Accrual Status: Closed to Accrual
Accrual Goal: 60
Current Accrual: 60

PI: Alan Ho, MD,Memorial Sloan-Kettering Cancer Center

Phase 1/2 Study of LOXO-292 in Patients WithAdvanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer(LIBRETTO- 001)
Accrual Status: Accruing

PI: Lori Wirth, MD Massachusetts General Hospital

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Accrual Status: Accruing

Bhavana Konda, MD, MPH.Ohio State University

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Accrual Status:Estimated to open for accrual June 2020


PI: Manisha Shah, MD,Ohio State University


ITOG Board of Directors -Call for Nominations opens today

Five (5) Board of Director-At-Large Positions

The ITOG Board of Directors invites the general membership to nominate members who are qualified and dedicated to the mission of this organization, to serve on the Board of Directors...The term of members of the Board of Directors is three years, commencing June 2020

There are currently five (5) Board of Director-At-Large Positions open for nomination.

The Best Resource for ITOG News is YOU!

We need your help to generate current, engaging content for the ITOG website. To facilitate this process, you can simply email a quick draft or idea to our in-house scientific writer, who will edit or write copy that will be reviewed and published to our site.
Please share the following for publication on the ITOG website:

·Thyroid Cancer News and Breakthroughs
·Clinical Trials
·Publications, Presentations
·Awards and Acknowledgements
·Promotions and Retirements
·Meetings and Events
·Industry News
·Patient Stories
·ITOG Announcements and Updates


Click Below to Submit News Item

Have You Updated your ITOG Membership Profile?

As a member, you will find access to our Member Directory, Community Forum, and Members Only information, including ITOG Clinical Trial Updates.

ITOG Members are making an impact on our mission to "Catalyze a Cure for Thyroid Cancer" and you can read about them here.


Paying your Membership

Making a Donation?

Credit Cards NowAccepted Online

We are proud to announce that ITOG website now acceptscredit cardsin additionto PayPal formembership dues anddonations.




Judy Dallas says...
Posted Thursday, May 21, 2020
Updated 5/21/2020

Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495


Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.